MAXONA Pharmaceuticals

MAXONA Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to developing innovative therapies that enhance patients' lives. With a focus on addressing the critical need for effective treatments for acute and chronic pain, MAXONA Pharmaceuticals is pioneering the next generation of pain management solutions, free from the side effects and addiction risks associated with traditional NSAIDs and opioids.

MAXONA Pharmaceuticals' lead compound, MAX-001, represents a significant advancement in pain therapy. This non-opioid, non-NSAID oral treatment features a novel mechanism of action and is initially being developed in the U.S. for both acute and chronic pain management. MAX-001 is a patent-protected, optimized formulation of nefopam, a widely used and extensively studied drug outside the U.S. MAXONA Pharmaceuticals is located at 101 Lindenwood Drive, Suite 225, Malvern, Pennsylvania 19355, US.

Driven by a vision to help patients maximize life, MAXONA Pharmaceuticals is committed to advancing clinical development and commercializing effective therapeutics. MAXONA Pharmaceuticals leverages its team's deep experience to realize its mission. We invite the manager of MAXONA Pharmaceuticals to create a customized and exclusive company showcase and product listing on our platform, showcasing MAXONA Pharmaceuticals's contributions to the pharmaceutical industry.